Bank of America’s TransCode Therapeutics RNAZ Stock Holding History

Bank of America’s Portfolio RNAZ Stock Details RNAZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8	Closed	-$55	–	6670
2025 Q4	$55	Hold	8	–	–	﹤0.01%	6938
2025 Q3	$86	Hold	8	–	–	﹤0.01%	7895
2025 Q2	$63	Buy	+8	New	+$74	﹤0.01%	8056
2025 Q1	–	Hold	0	–	–	–	8259
2024 Q4	–	Hold	0	–	–	–	8072
2024 Q3	–	Hold	0	–	–	–	7756
2024 Q2	–	Hold	0	–	–	–	7821
2024 Q1	–	Hold	0	–	-$266	–	8109
2023 Q4	–	Hold	0	–	–	–	7339

Other funds holding RNAZ

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Bank of America's RNAZ Position: Q1 2026 in Review

Bank of America sold out of TransCode Therapeutics (RNAZ) in Q1 2026, closing a stake of 8 shares — an estimated $55 sold.

Bank of America first reported a position in RNAZ in Q2 2025 and held it in 3 quarters. The position peaked at $86 in Q3 2025. 8 funds tracked by Wall St. Rank hold RNAZ as of Q1 2026.

Bank of America reported no remaining TransCode Therapeutics position as of Q1 2026 after selling out during the quarter.
Bank of America sold 8 TransCode Therapeutics shares in Q1 2026, an estimated $55.
Bank of America first reported a position in TransCode Therapeutics in Q2 2025 and held it in 3 quarters.
Bank of America's TransCode Therapeutics position peaked at $86 in Q3 2025.
8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.